[go: up one dir, main page]

NO20062432L - Farmasoytiske formuleringer for baeremedierte transportstatiner og anvendelse derav - Google Patents

Farmasoytiske formuleringer for baeremedierte transportstatiner og anvendelse derav

Info

Publication number
NO20062432L
NO20062432L NO20062432A NO20062432A NO20062432L NO 20062432 L NO20062432 L NO 20062432L NO 20062432 A NO20062432 A NO 20062432A NO 20062432 A NO20062432 A NO 20062432A NO 20062432 L NO20062432 L NO 20062432L
Authority
NO
Norway
Prior art keywords
statin
carrier
mediated transport
present
formulations
Prior art date
Application number
NO20062432A
Other languages
English (en)
Inventor
John G Devane
Jackie Butler
Paul Stark
Original Assignee
Athpharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athpharma Ltd filed Critical Athpharma Ltd
Publication of NO20062432L publication Critical patent/NO20062432L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Foreliggende oppfinnelse gjelder formuleringer som omfatter terapeutisk effektive mengder av minst ett syrestabilt statin med bærerformidlet transport, minst ett lite vannløselig statin med bærerformidlet transport eller minst ett høymolekylært statin med bærerformidlet transport, f.eks. atorvastatin og rosuvastatin, eller et farmasøytisk aksepterbart salt derav og fremgangsmåter for anvendelse derav. De foreliggende formuleringer og fremgangsmåter er utformet for å gi en kontrollert frigjøring av en terapeutisk mengde av statinet i tynntarmen, slik at den systemiske eksponering av statinet begrenses og den leverspesifikke absorpsjonen av medikamentet maksimaliseres. Formuleringen og fremgangsmåten ifølge foreliggende oppfinnelse er spesielt anvendbare for behandling og/eller forebyggelse av tilstander som bedres ved å redusere nivået av lipider og/eller kolesterol i kroppen.
NO20062432A 2003-11-04 2006-05-29 Farmasoytiske formuleringer for baeremedierte transportstatiner og anvendelse derav NO20062432L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51677003P 2003-11-04 2003-11-04
US10/967,167 US8987322B2 (en) 2003-11-04 2004-10-19 Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
PCT/IB2004/003849 WO2005041939A1 (en) 2003-11-04 2004-10-29 Pharmaceutical formulations for carrier-mediated transport statins and uses thereof

Publications (1)

Publication Number Publication Date
NO20062432L true NO20062432L (no) 2006-08-04

Family

ID=34556205

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062432A NO20062432L (no) 2003-11-04 2006-05-29 Farmasoytiske formuleringer for baeremedierte transportstatiner og anvendelse derav

Country Status (9)

Country Link
US (2) US8987322B2 (no)
EP (2) EP1682095B1 (no)
JP (1) JP2007510714A (no)
AU (1) AU2004284884A1 (no)
CA (1) CA2543716C (no)
ES (2) ES2509869T3 (no)
IL (1) IL175134A0 (no)
NO (1) NO20062432L (no)
WO (1) WO2005041939A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
CA2628666A1 (en) * 2005-11-21 2007-05-24 Teva Pharmaceutical Industries Ltd. Atorvastatin formulation
CN101330919B (zh) * 2005-12-20 2012-12-05 力奇制药公司 包含(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲磺酰基)氨基]嘧啶-5-基]-(3r,5s)-3,5-二羟基庚-6-烯酸的药物组合物
CA2644905A1 (en) * 2006-03-06 2007-09-13 Teva Pharmaceutical Industries Ltd. Ezetimibe compositions
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
ES2300188B1 (es) * 2006-05-24 2009-05-01 Ferrer Internacional, S.A. Comprimido bicapa para la prevencion de los accidentes cardiovasculares.
US20090087490A1 (en) 2007-06-08 2009-04-02 Addrenex Pharmaceuticals, Inc. Extended release formulation and method of treating adrenergic dysregulation
US20090082315A1 (en) * 2007-09-05 2009-03-26 Raif Tawakol Compositions and Methods for Controlling Cholesterol Levels
TR200800269A2 (tr) * 2008-01-15 2009-08-21 Bi̇li̇m İlaç Sanayi̇ Ti̇caret A.Ş. Stabil farmasötik formülasyon ve hazırlama yöntemleri
TWI391150B (zh) * 2008-01-22 2013-04-01 Taiwan Biotech Co Ltd 腸溶性長效塗覆芯與藥物劑型及其製造方法
BRPI0906728A2 (pt) * 2008-01-30 2015-07-07 Lupin Ltd Formulação modificadas da liberação de inibidores do reductase de hmg coa
WO2009137080A1 (en) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of gnrh related compounds and processes of preparation
US20100215743A1 (en) * 2009-02-25 2010-08-26 Leonard Thomas W Composition and drug delivery of bisphosphonates
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (en) * 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
KR20140026354A (ko) 2011-01-07 2014-03-05 메리온 리서치 Ⅲ 리미티드 경구 투여용 철의 제약 조성물
EP3250191B1 (en) 2015-01-29 2024-01-17 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4088884A (en) * 1976-01-26 1978-05-09 The United States Of America As Represented By The Secretary Of The Navy Wide aperture optical communications detector
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4557925A (en) * 1982-07-08 1985-12-10 Ab Ferrosan Membrane-coated sustained-release tablets and method
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
US4904474A (en) * 1988-01-25 1990-02-27 Alza Corporation Delivery of drug to colon by oral disage form
CA2045428A1 (en) 1990-06-26 1991-12-27 Alfred W. Alberts Method for enhancing the lowering of plasma cholesterol levels
US6764697B1 (en) * 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5573776A (en) * 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
CO5140079A1 (es) 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
JP2002538202A (ja) * 1999-03-08 2002-11-12 メルク エンド カムパニー インコーポレーテッド ＨＭＧ−ＣｏＡレダクターゼ阻害剤のジヒドロキシオープンアシッド及びその塩
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
AU2001253401B2 (en) * 2000-04-11 2006-12-07 Atherogenics, Inc Compounds and methods to increase plasma hdl cholesterol levels and improve hdl functionality
US20020147232A1 (en) * 2000-05-26 2002-10-10 Claus Sundgreen Pharmaceutical compositions comprising desglymidodrine as an active drug substance
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
EP1465605A1 (en) 2002-01-11 2004-10-13 Athpharma Limited Pravastatin pharmaceutical formulations and methods of their use
MXPA05002095A (es) 2002-09-03 2005-06-06 Biovail Lab Int Srl Formulaciones farmaceuticas de pravastatina y metodos de su uso.
JP2006503023A (ja) 2002-09-03 2006-01-26 バイオヴェイル ラボラトリーズ インコーポレイテッド スタチン薬物の放出調節ための医薬品製剤および方法

Also Published As

Publication number Publication date
CA2543716A1 (en) 2005-05-12
IL175134A0 (en) 2006-09-05
EP1682095B1 (en) 2014-07-02
US20150164893A1 (en) 2015-06-18
EP2319501B1 (en) 2014-06-18
ES2500924T3 (es) 2014-10-01
EP2319501A1 (en) 2011-05-11
US20050119331A1 (en) 2005-06-02
EP1682095A1 (en) 2006-07-26
US8987322B2 (en) 2015-03-24
JP2007510714A (ja) 2007-04-26
CA2543716C (en) 2016-05-31
AU2004284884A1 (en) 2005-05-12
ES2509869T3 (es) 2014-10-20
WO2005041939A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
NO20062432L (no) Farmasoytiske formuleringer for baeremedierte transportstatiner og anvendelse derav
EA200900155A1 (ru) Модуляторы фармакокинетических свойств лекарственных средств
NO20061325L (no) Kombinasjon av legemidler for behandling av neoplasmer
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
NO20075042L (no) Farmasoytisk sammensetning innbefattende en omega-karboksyarylsubstituert difenylurea for behandling av cancer
DE60219954D1 (de) Neue Indol-2-on Derivate
BRPI0416752A (pt) composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica
EA200970435A1 (ru) Лечение общих расстройств развития
DE60315479D1 (de) Pyrimidinamid derivate und deren verwendung
CY1115719T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
NO20065904L (no) Terapeutiske forbindelser
BRPI0409427A (pt) composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
NO20023486L (no) Forbindelser av pyrroltypen, perapater inneholdende forbindelser samt deres anvendelse for behandling av cancer- ogvirale sykdommer
WO2003020214A3 (en) Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
NO20021437L (no) Fremgangsmate til forebyggelse av colorektal kreft
EA200870223A1 (ru) Производные бензоизоиндола для лечения боли
NO20074661L (no) Anvendelse av en forbindelse
UY30557A1 (es) Tratamiento y prevencion de la fibrosis intestinal
ATE333897T1 (de) Arzneimittel mit chymaseinhibitoren als wirksames mittel zur behandlung von dermatitis mit zweiphasigen hautreaktionen
EE200200556A (et) Midodriini ja/või desglümidodriini sisaldav kontrollitud vabanemisega farmatseutiline kompositsioon
CY1105545T1 (el) Θεραπεια στατινης για ενισχυση της διατηρησης νοητικης λειτουργιας
SE0203817D0 (sv) New composition
BRPI0410576A (pt) composto quìmico, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método para o tratamento, prevenção ou alìvio de uma doença ou um distúrbio ou condição de um corpo de animal vivo

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application